You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Allogeneic CAR-T

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)

Not yet recruiting
  • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 28, 2022

Relapsed/Refractory Large B Cell Lymphoma Trial (biological, drug, genetic)

Not yet recruiting
  • Relapsed/Refractory Large B Cell Lymphoma
  • ALLO-647
  • +3 more
  • (no location specified)
Feb 6, 2023

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL Trial (ThisCART19A)

Not yet recruiting
  • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL
  • (no location specified)
Sep 9, 2022

Study of Participants Who ReceivedAllogeneic CAR T-Cell Product

Recruiting
  • Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
    • Culver City, California
      Science 37, Inc.
    Apr 10, 2023

    Refractory or Relapsed B Cell Lymphoma Trial in Chongqing (ThisCART19A, Fludarabine, Cyclophosphamide)

    Not yet recruiting
    • Refractory or Relapsed B Cell Lymphoma
    • Chongqing, Chongqing, China
      Chongqing University Cancer Hospital
    Mar 8, 2023

    Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial (ThisCART19A, Fludarabine Oral Tablet, Cyclophosphamide)

    Not yet recruiting
    • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
    • (no location specified)
    Oct 8, 2022

    CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level

    Recruiting
    • CAR
    • +2 more
    • ThisCART19A with Dose Level 1
    • ThisCART19A with Dose Level 2
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jan 18, 2023

    T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

    Not yet recruiting
    • T-Cell Non-Hodgkin Lymphoma
    • +14 more
    • WU-CART-007
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 17, 2023

    Relapsed Acute Myeloid Leukaemia Trial (Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL))

    Not yet recruiting
    • Relapsed Acute Myeloid Leukaemia
    • Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
    • (no location specified)
    Jul 4, 2023

    Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

    Not yet recruiting
    • Non Hodgkin's Lymphoma
    • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
    • +2 more
    • Beijing, China
    • +2 more
    Aug 23, 2023

    B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • (no location specified)
    Oct 10, 2023

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

    Not yet recruiting
    • Acute Myeloid Leukemia, in Relapse
    • Acute Myeloid Leukemia Refractory
    • (no location specified)
    Nov 9, 2023

    Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

    Not yet recruiting
    • Solid Tumor
    • HLA-G-CAR.BiTE allogeneic γδ T cells
    • Taichung, Non-US, Taiwan
      China Medical University Hospital
    Nov 27, 2023

    CB-Long-Term Safety Study (CB-LTSS)

    Enrolling by invitation
    • Lymphoma, Non-Hodgkin
    • +7 more
    • Allogeneic CAR-T therapy
    • Irvine, California
    • +3 more
    Nov 18, 2022

    T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Australia, United States (WU-CART-007)

    Recruiting
    • T-cell Acute Lymphoblastic Leukemia
    • Lymphoblastic Lymphoma
    • WU-CART-007
    • Duarte, California
    • +7 more
    Jun 22, 2022

    Systemic Lupus Erythematosus (SLE) Trial (BRL-301)

    Not yet recruiting
    • Systemic Lupus Erythematosus (SLE)
    • BRL-301
    • (no location specified)
    Aug 13, 2023

    Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

    Not yet recruiting
    • Chronic Graft Versus Host Disease
    • +2 more
    • Biopsy
    • +11 more
    • Duarte, California
      City of Hope Medical Center
    Aug 7, 2023

    Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)

    Recruiting
    • Hematologic Diseases
    • Neoplasms
    • CD7 CAR-T cells injection
    • Allogeneic hematopoietic stem cell transplantation
    • Hangzhou, Zhejiang, China
      The first affiliated hospital of medical college of zhejiang uni
    Apr 11, 2023

    Relapsed/Refractory Multiple Myeloma Trial in New York, Nashville, Salt Lake City (CB-011)

    Recruiting
    • Relapsed/Refractory Multiple Myeloma
    • CB-011
    • New York, New York
    • +3 more
    Feb 15, 2023

    Study for Patients Treat With WU-CART-007

    Enrolling by invitation
    • T-cell Acute Lymphoblastic Leukemia
    • T-cell Lymphoblastic Lymphoma
    • Genetic: WU-CART-007
    • Saint Louis, Missouri
      Washington University
    Aug 18, 2022

    Relapsed/Refractory Multiple Myeloma Trial in United States (genetic, biological, drug)

    Recruiting
    • Relapsed/Refractory Multiple Myeloma
    • ALLO-605
    • +3 more
    • Denver, Colorado
    • +3 more
    Feb 9, 2022

    Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

    Not yet recruiting
    • Lymphoid Leukemia
    • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
    • Treg CD34+ HSPC (Orca-T)
    • Palo Alto, California
      Stanford Cancer Center
    Aug 17, 2022

    Lymphoma Leukemia Trial in Minneapolis (allogeneic CAR19 regulatory T cells (CAR19-tTreg))

    Not yet recruiting
    • Lymphoma Leukemia
    • allogeneic CAR19 regulatory T cells (CAR19-tTreg)
    • +2 more
    • Minneapolis, Minnesota
      Masonic Cancer Center - University of Minnesota
    Dec 6, 2022

    Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

    Recruiting
    • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
    • Classical Hodgkin Lymphoma
    • CD30.CAR-EBVST cells
    • Houston, Texas
    • +1 more
    Jul 20, 2022

    Relapse Leukemia, Refractory Leukemia Trial in Shenzhen (Allogeneic CD19 CAR-T cells)

    Recruiting
    • Relapse Leukemia
    • Refractory Leukemia
    • Allogeneic CD19 CAR-T cells
    • Shenzhen, Guangdong, China
      Li Yu
    Dec 7, 2021